Basics |
AquaBounty Technologies, Inc.
AquaBounty Technologies Inc is a biotechnology company. The company is engaged in the business of conducting research and development of the commercial viability of a group of proteins known as antifreeze proteins.
|
IPO Date: |
January 9, 2017 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$2.52M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.14 | 3.94%
|
Avg Daily Range (30 D): |
$0.04 | 4.90%
|
Avg Daily Range (90 D): |
$0.03 | 4.33%
|
Institutional Daily Volume |
Avg Daily Volume: |
.49M |
Avg Daily Volume (30 D): |
1.57M |
Avg Daily Volume (90 D): |
.76M |
Trade Size |
Avg Trade Size (Sh.): |
190 |
Avg Trade Size (Sh.) (30 D): |
413 |
Avg Trade Size (Sh.) (90 D): |
422 |
Institutional Trades |
Total Inst.Trades: |
125 |
Avg Inst. Trade: |
$1.52M |
Avg Inst. Trade (30 D): |
$.52M |
Avg Inst. Trade (90 D): |
$.52M |
Avg Inst. Trade Volume: |
.01M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$2.13M |
Avg Closing Trade (30 D): |
$M |
Avg Closing Trade (90 D): |
$M |
Avg Closing Volume: |
21.76K |
|
|
|
|
News |
May 15, 2024 @ 2:20 PM
AquaBounty Technologies, Inc. (AQB) Reports Q1 Los...
Source: Zacks Equity Research
|
May 14, 2024 @ 1:10 PM
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Reve...
Source: Zacks Equity Research
|
May 13, 2024 @ 9:10 PM
Cara Therapeutics (CARA) Reports Q1 Loss, Misses R...
Source: Zacks Equity Research
|
May 8, 2024 @ 9:45 PM
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, To...
Source: Zacks Equity Research
|
Oct 16, 2023 @ 12:47 PM
Why ContraFect Shares Are Trading Higher By Around...
Source: Lisa Levin
|
Financials |
|
TTM |
Q4 2024 |
FY 2024 |
Basic EPS
|
$-38.65
|
$-21.78
|
$-38.65
|
Diluted EPS
|
$-38.65
|
$-21.78
|
$-38.65
|
Revenue
|
$ M
|
$ -.71M
|
$ M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -149.19M
|
$ -84.12M
|
$ -149.19M
|
Operating Income / Loss
|
$ -111.44M
|
$ -48.61M
|
$ -111.44M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ -8.97M
|
$ -.27M
|
$ -8.97M
|
PE Ratio
|
|
|
|
Splits |
Oct 16, 2023:
20:1
|
Jan 05, 2017:
30:1
|
|